Natural killer (NK) cells are the human body’s first line of defense against cancer and infections but tend to get knocked down by treatment with anti-CD38 antibodies. This is because NK cells ...

CAR NK cells are following closely behind. Cytovia has designed CAR NK cells against three targets: EGFR, GPC3 and CD38. The EGFR candidate is a dual-targeted CAR designed to hit both wild-type ...

CARsgen Therapeutics Holdings Limited, a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumours, announces that KJ-C2320, an allogeneic CAR ...

ONK’s subsequent NK-cell therapy, ONKT102, has a CD38 CAR with optimised affinity and a DR5 TRAIL variant. ONKT102 is designed to treat relapsed or refractory multiple myeloma (MM), a highly ...

The firm's products include CD38-GEAR-NK, CD38-Diagnostic and GEAR-NK Product. The company was founded in 2017 and is headquartered in Wexford, PA.

About THANK-uCAR® THANK (Target to Hinder the Attack of NK cells)-uCAR® is CARsgen's proprietary technology to generate allogeneic CAR-T cells with improved expansion and persis ...

an allogeneic CAR T-cell therapy targeting CD38, has administered the first dose to a patient in an investigator-initiated trial (IIT).

an allogeneic CAR T-cell therapy targeting CD38, has administered the first dose to a patient in an investigator-initiated trial (IIT). KJ-C2320 is developed based on CARsgen's THANK-uCAR ® platform.